10 stories mentioning ROIVUpdated 28d ago
Every FINWIRES story that references ROIV, newest first.
Melissa B, Epperly, Director, on June 29, 2026, sold 17,750 shares in Roivant Sciences (ROIV) for $610,252. Following the Form 4 filing with the SEC, Epperly has control over a total of 16,474 common shares of the company, with 16,474 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000180735926000010/xslF345X05/wk-form4_1782945259.xml
Keith S Manchester, Director, on June 26, 2026, sold 1,638,163 shares in Roivant Sciences (ROIV) for $56,444,076. Following the Form 4 filing with the SEC, Manchester has control over a total of 15,437,569 common shares of the company, with 1,748,403 shares held directly and 13,689,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000119312526291172/xslF345X05/ownership.xml
Daniel Allen Gold, Director, on June 26, 2026, sold 1,438,163 shares in Roivant Sciences (ROIV) for $49,354,076. Following the Form 4 filing with the SEC, Gold has control over a total of 13,689,166 common shares of the company, with 13,689,166 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000119312526291163/xslF345X05/ownership.xml
Mayukh Sukhatme, Director, President & Chief Investment Officer, on June 25, 2026, sold 1,000,000 shares in Roivant Sciences (ROIV) for $34,105,000. Following the Form 4 filing with the SEC, Sukhatme has control over a total of 18,677,617 common shares of the company, with 18,677,617 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000073/xslF345X05/wk-form4_1782771783.xml
Eric Venker, President & Immunovant Chief Executive Officer, on June 24, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $6,631,268. Following the Form 4 filing with the SEC, Venker has control over a total of 1,613,063 common shares of the company, with 1,613,063 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000071/xslF345X05/wk-form4_1782512028.xml
Eric Venker, President & Immunovant Chief Executive Officer, on May 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $6,054,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,613,063 common shares of the company, with 1,613,063 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000065/xslF345X05/wk-form4_1779488744.xml
Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.8%.Roivant Sciences (ROIV) stock was up nearly 6% after the company reported that it swung to a fiscal Q4 net income.ImmunityBio's (IBRX) supplemental biologics license application for Anktiva in combination with Bacillus Calmette-Guerin in patients with bladder cancer with papillary disease has been accepted for review by the US Food and Drug Administration, the company said. ImmunityBio shares were 8% higher pre-bell.Natera (NTRA) stock was up more than 2% after the company said the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.
Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.6%.Roivant Sciences (ROIV) stock was up more than 8% after the company reported that it swung to a fiscal Q4 net income.
Eric Venker, President & Immunovant Chief Executive Officer, on April 20, 2026, sold 200,000 shares in Roivant Sciences (ROIV) for $5,918,000. Following the Form 4 filing with the SEC, Venker has control over a total of 1,647,546 common shares of the company, with 1,647,546 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000044/xslF345X05/wk-form4_1776896865.xml
Matthew Gline, Director, Chief Executive Officer, on April 16, 2026, sold 289,774 shares in Roivant Sciences (ROIV) for $8,449,810. Following the Form 4 filing with the SEC, Gline has control over a total of 16,736,116 common shares of the company, with 16,736,116 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1635088/000163508826000038/xslF345X05/wk-form4_1776724041.xml
